3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Multiple Myeloma
55
Recurrence
7
Lymphoma
6
Neoplasms, Plasma Cell
5
Immunoglobulin Light-chain Amyloidosis
4
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Paraproteinemias
2
Neoplasms
2
Lymphoma, T-Cell
2
Lymphoma, Mantle-Cell
2
Leukemia, Myeloid, Acute
2
beta-Thalassemia
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Thalassemia
1
Sarcoma, Myeloid
1
Prostatic Neoplasms
1
Plasmablastic Lymphoma
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Multi-centric Castleman's Disease
1
Macular dystrophy, corneal type 1
1
Lymphoproliferative Disorders
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma, B-Cell
1
Lymphadenopathy
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Interventions
Magnetic Resonance Spectroscopy
8
Specimen Handling
5
Nivolumab
5
selpercatinib
4
Iodine-124
4
Biopsy
4
binimetinib
3
Iodine-131
3
Cetuximab
3
ulixertinib
2
trametinib
2
pembrolizumab
2
omipalisib
2
larotrectinib
2
defactinib
2
dabrafenib
2
Surveys and Questionnaires
2
Sunitinib
2
Radiosurgery
2
Ipilimumab
2
Immunoglobulin G
2
Gemcitabine
2
Disulfides
2
Cyclophosphamide
2
CTLA-4 Antigen
2
trastuzumab deruxtecan
1
trastuzumab biosimilar HLX02
1
tipifarnib
1
temsirolimus
1
sapanisertib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Thyroid Neoplasms
×
Bortezomib
×
90 days
×
Clear all
No trials found.